Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuronetics Inc (DE:NRC)
FRANKFURT:NRC
Neuronetics (NRC) Stock Price & Analysis
0 Followers
NRC Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.94 - €4.40
Previous Close€1.64
Volume0.00
Average Volume (3M)193.00
Market Cap
€50.37M
Enterprise Value€52.96M
Total Cash (Recent Filing)$59.70M
Total Debt (Recent Filing)$62.47M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 06, 2024EPS Estimate
-€0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,997,563
10 Day Avg. Volume0
30 Day Avg. Volume193
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.61
Price to Sales (P/S)0.68
Price to Cash Flow (P/CF)6.40
P/FCF Ratio5.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda-2.31
Forecast
1Y Price Target
€6.08Price Target Upside269.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Neuronetics News
PremiumCompany Announcements
Neuronetics to Discuss Future Outlook at Growth Stock Conference
PremiumCompany Announcements
Neuronetics Inc Releases New Investor Presentation for May 2024Bulls Say, Bears Say
Bulls Say
FDA ClearanceFDA clearance of first-line treatment of major depressive disorder (MDD) in adolescent patients will expand Neuronetics’ total addressable market by 35%, and the company is already gaining interest from providers prior to its launch.
Market PositionNeuroStar is now the first and only transcranial magnetic stimulation (TMS) treatment cleared for the treatment of major depressive disorder in patients aged 15-21.
Revenue GrowthThe company is on the path to profitability with its revenue growth, margin profile, and operating expense improvement.
Bears Say
Capital Sales ImpactThe company's capital sales were negatively impacted by the Change Healthcare cybersecurity breach as well as longer-than-expected average time for customers to secure credit.
Customer PaymentsThe disruption also delayed some customer payments to STIM, resulting in a $3 mln cash shortfall to the company.
Revenue GuidanceQ2/24 revenue was guided to $18.0M-$19.0M, below CG/Street estimates of $19.5M.
---
Options Prices
Currently, No data available
---
Ownership Overview
28.96% Insiders
13.47% Mutual Funds
46.42% Other Institutional Investors
11.15% Public Companies and
Individual Investors
NRC FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was €0.94 and its highest was €4.40 in the past 12 months.
What is Neuronetics Inc’s market cap?
Currently, no data Available
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Aug 06, 2024 which is in 37 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on May 07, 2024. The company reported -€0.252 earnings per share for the quarter, beating the consensus estimate of -€0.289 by €0.037.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -€0.25.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 29,997,562 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -€0.252 in its last earnings report, beating expectations of -€0.289. Following the earnings report the stock price went down -0.731%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Among the largest hedge funds holding Neuronetics Inc’s share is First Eagle Investment Management LLC. It holds Neuronetics Inc’s shares valued at 4M.
---
Neuronetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.08 (269.82% Upside)
€6.08 (269.82% Upside)
Blogger Sentiment
Bearish
DE:NRC Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $102.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.27%
12-Months-Change
Fundamentals
Return on Equity
-72.48%
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
---
NRC Earnings Call
Q1 2024
0:00 / 0:00
---
NRC Stock 12 Month Forecast
Average Price Target
€6.08
▲(269.82% Upside)
Technical Analysis
Neuronetics
―
Medtronic
―
Edwards Lifesciences
―
Abbott Laboratories
―
Boston Scientific
―
Best Analysts Covering NRC
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-9.54%
reiterated a buy rating 4 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -9.54% per trade.
---